Is PT-141 (Bremelanotide) Legal in Missouri?
HealthRX.com
Vyleesi is FDA-approved; compounded PT-141 is not
Key numbers
- 1.75 mgApproved Vyleesi strength, given as a prefilled subcutaneous autoinjectorSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 40.0%Share of Vyleesi users with nausea, versus 1.3% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 6 mmHgMaximal systolic blood pressure rise after one Vyleesi doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 1%Share of patients on up to 8 doses a month with focal hyperpigmentation, versus none on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
See the public record for Bremelanotide
At a glance
- Federal status / Prescription drug, approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
- Approved indication / Acquired, generalized HSDD in premenopausal women [1]
- Not approved for / Men, postmenopausal women, or enhancing sexual performance [1]
- Boxed warning / None [1]
- Compounded PT-141 / Not an FDA-approved drug; not reviewed by FDA before marketing [3]
- FDA bulk-substance lists / Bremelanotide in no category [4]
Is PT-141 legal in Missouri?
Vyleesi is the FDA-approved bremelanotide product: 1.75 mg in a prefilled subcutaneous autoinjector, prescription only, approved June 21, 2019 under NDA 210557 and now held by Cosette Pharmaceuticals [1][2][5]. Its approved use is premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or interpersonal difficulty and is not due to a coexisting medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says it is not indicated for postmenopausal women, for men, or to enhance sexual performance [1].
Questions worth asking
What is actually sold as PT-141
Compounded bremelanotide is not an FDA-approved drug, and FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients [3]. A vial sold as a research-use peptide is not Vyleesi and is not an approved drug product [6].
Bremelanotide appears in no category on FDA's bulk-substance lists and is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4][7].
What the label says to watch for
The label lists uncontrolled hypertension or known cardiovascular disease as contraindications and says Vyleesi is not recommended for people at high cardiovascular risk [1]. Each dose raises blood pressure briefly: maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down up to 5 beats per minute and values usually back to baseline within 12 hours [1]. Nausea occurred in 40.0% versus 1.3% on placebo, with 13% needing an anti-nausea medicine and 8% stopping [1]. Focal hyperpigmentation, including the face, gums and breasts, was reported by 1% of patients taking up to 8 doses a month versus none on placebo [1]. The label says to avoid Vyleesi with oral naltrexone products intended to treat alcohol or opioid addiction [1]. There is no boxed warning [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Frequently asked questions
Is PT-141 legal in Missouri?
Is PT-141 FDA-approved?
Does Vyleesi have a boxed warning or a REMS?
Is compounded or research-use PT-141 an approved drug?
What are the common side effects of bremelanotide?
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Human Drug Compounding Laws | FDA.
- U.S. Food and Drug Administration.
- Drugs@FDA: FDA-Approved Drugs.
- Official web page.
- Official web page.
- Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.